Suppr超能文献

外泌体miR-182-5p是恶性胸腔积液的一种潜在诊断标志物。

Exosomal miR-182-5p is a potential diagnostic marker for malignant pleural effusion.

作者信息

Zhao Wen, Wen Jian-Xun, Niu Yan, Yan Li, Wang Mei-Ying, Jiao Wei, Wang Ya-Fei, Gao Wen-Hui, Yang Dan-Ni, Zheng Wen-Qi, Hu Zhi-De

机构信息

Center for Clinical Epidemiology Research, the Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.

Department of Laboratory Medicine, the Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.

出版信息

Transl Lung Cancer Res. 2025 Apr 30;14(4):1138-1148. doi: 10.21037/tlcr-2024-1205. Epub 2025 Apr 16.

Abstract

BACKGROUND

Biomarkers in pleural fluid are the potential auxiliary diagnostic markers for malignant pleural effusion (MPE). Exosomal microRNAs (miRNAs) represent novel diagnostic markers for various diseases. The diagnostic performance of exosomal miRNAs for MPE remains unclear. Therefore, we examined the exosomal miRNAs profiles of both MPE and benign pleural effusion (BPE), aiming to study diagnostic performance of exosomal miRNAs for MPE.

METHODS

We used next-generation sequencing (NGS) technology to analyze the pleural fluid exosomal miRNA profile in five MPE and 15 BPE cases. We analyzed the differentially expressed exosomal miRNAs by reverse transcription polymerase chain reaction (RT-PCR), with cel-miR-39 or snRNA U6 as internal references. We assessed the diagnostic accuracy of exosomal miRNA for MPE with a receiver operating characteristic (ROC) curve. We also analyzed whether exosomal miRNA could improve the diagnostic performance of pleural carcinoembryonic antigen (CEA).

RESULTS

Fifty-eight miRNAs were up-regulated, and 35 miRNAs were down-regulated in MPE. We selected exosomal miR-182-5p for further study and analyzed miR-182-5p in 153 patients with undiagnosed pleural effusion. Exosomal miR-182-5p was undetectable in 32 participants. In the remaining participants with 49 MPE and 72 BPE cases, we found that the areas under the curve (AUCs) and their 95% confidence intervals (95% CIs) for exosomal miR-182-5p were 0.78 (95% CI: 0.69-0.86) when using cel-miR-39 as an internal reference, and 0.80 (95% CI: 0.73-0.88) when using snRNA U6. The combination of exosomal miR-182-5p and CEA can slightly improve the diagnostic accuracy of MPE, with an AUC of 0.91 (95% CI: 0.85-0.97).

CONCLUSIONS

Pleural miR-182-5p can assist in the diagnosis of MPE. Its diagnostic performance is slightly affected by internal reference.

摘要

背景

胸腔积液中的生物标志物是恶性胸腔积液(MPE)潜在的辅助诊断标志物。外泌体微小RNA(miRNA)是多种疾病的新型诊断标志物。外泌体miRNA对MPE的诊断性能尚不清楚。因此,我们检测了MPE和良性胸腔积液(BPE)的外泌体miRNA谱,旨在研究外泌体miRNA对MPE的诊断性能。

方法

我们使用下一代测序(NGS)技术分析了5例MPE和15例BPE病例的胸腔积液外泌体miRNA谱。我们以cel-miR-39或小核RNA U6为内参,通过逆转录聚合酶链反应(RT-PCR)分析差异表达的外泌体miRNA。我们用受试者工作特征(ROC)曲线评估外泌体miRNA对MPE的诊断准确性。我们还分析了外泌体miRNA是否能提高胸腔癌胚抗原(CEA)的诊断性能。

结果

MPE中有58个miRNA上调,35个miRNA下调。我们选择外泌体miR-182-5p进行进一步研究,并在153例未确诊胸腔积液患者中分析miR-182-5p。32名参与者中未检测到外泌体miR-182-5p。在其余49例MPE和72例BPE病例的参与者中,我们发现以cel-miR-39为内参时,外泌体miR-182-5p的曲线下面积(AUC)及其95%置信区间(95%CI)为0.78(95%CI:0.69-0.86),以小核RNA U6为内参时为0.80(95%CI:0.73-0.88)。外泌体miR-182-5p和CEA联合使用可略微提高MPE的诊断准确性,AUC为0.91(95%CI:0.85-0.97)。

结论

胸腔miR-182-5p可辅助MPE的诊断。其诊断性能受内参的影响较小。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/61a3/12082201/94d05ffd8716/tlcr-14-04-1138-f1.jpg

相似文献

1
Exosomal miR-182-5p is a potential diagnostic marker for malignant pleural effusion.
Transl Lung Cancer Res. 2025 Apr 30;14(4):1138-1148. doi: 10.21037/tlcr-2024-1205. Epub 2025 Apr 16.
5
Identification of suitable reference genes for the relative quantification of microRNAs in pleural effusion.
Oncol Lett. 2014 Oct;8(4):1889-1895. doi: 10.3892/ol.2014.2404. Epub 2014 Aug 1.
7
Exosomal miRNA-profiling of pleural effusion in lung adenocarcinoma and tuberculosis.
Front Surg. 2023 Jan 6;9:1050242. doi: 10.3389/fsurg.2022.1050242. eCollection 2022.
8
Diagnostic Value of Six Tumor Markers for Malignant Pleural Effusion in 1,230 Patients: A Single-Center Retrospective Study.
Pathol Oncol Res. 2022 Apr 20;28:1610280. doi: 10.3389/pore.2022.1610280. eCollection 2022.
9
[The value of B7-H4 and carcinoembryonic antigen in diagnosing the benign and malignant pleural effusion].
Zhonghua Zhong Liu Za Zhi. 2017 Jul 23;39(7):524-527. doi: 10.3760/cma.j.issn.0253-3766.2017.07.009.
10
Pleural carbohydrate antigen 50 and malignant pleural effusion: a prospective, double-blind diagnostic accuracy test.
Transl Lung Cancer Res. 2024 May 31;13(5):1061-1068. doi: 10.21037/tlcr-24-68. Epub 2024 May 29.

本文引用的文献

1
Tumor markers determination in malignant pleural effusion: pearls and pitfalls.
Clin Chem Lab Med. 2024 Aug 16;63(3):515-520. doi: 10.1515/cclm-2024-0542. Print 2025 Feb 25.
3
Pleural carbohydrate antigen 50 and malignant pleural effusion: a prospective, double-blind diagnostic accuracy test.
Transl Lung Cancer Res. 2024 May 31;13(5):1061-1068. doi: 10.21037/tlcr-24-68. Epub 2024 May 29.
4
Pleural fluid soluble Fas ligand and tuberculous pleural effusion: a prospective diagnostic test accuracy study.
J Thorac Dis. 2023 Dec 30;15(12):6493-6501. doi: 10.21037/jtd-23-1076. Epub 2023 Dec 6.
6
Exosomal miRNA-profiling of pleural effusion in lung adenocarcinoma and tuberculosis.
Front Surg. 2023 Jan 6;9:1050242. doi: 10.3389/fsurg.2022.1050242. eCollection 2022.
7
Extracellular Vesicle MicroRNA in Malignant Pleural Effusion.
Genes (Basel). 2022 Nov 19;13(11):2159. doi: 10.3390/genes13112159.
8
Pleural fluid biochemical analysis: the past, present and future.
Clin Chem Lab Med. 2022 Nov 17;61(5):921-934. doi: 10.1515/cclm-2022-0844. Print 2023 Apr 25.
9
Diagnostic utility of pleural cell-free nucleic acids in undiagnosed pleural effusions.
Clin Chem Lab Med. 2022 Jul 4;60(10):1518-1524. doi: 10.1515/cclm-2022-0519. Print 2022 Sep 27.
10
Diagnostic sensitivity of pleural fluid cytology in malignant pleural effusions: systematic review and meta-analysis.
Thorax. 2023 Jan;78(1):32-40. doi: 10.1136/thoraxjnl-2021-217959. Epub 2022 Feb 2.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验